Kyowa Kirin Co., Ltd.
4151
Classement en actions
#2397
Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused... Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused on the discovery, development, manufacturing, and marketing of innovative medical therapies. The company's core areas of expertise span oncology, nephrology, central nervous system disorders, and immunology. Its extensive product portfolio includes established medications such as ABSTRAL, a sublingual fentanyl formulation for managing breakthrough pain in cancer patients; ALLELOCK, an antihistamine for various allergic conditions; and CONIEL, a calcium channel blocker prescribed for hypertension and angina. Kyowa Kirin also provides a range of advanced biological and specialized treatments. These encompass Crysvita, a recombinant human monoclonal IgG1 antibody targeting fibroblast growth factor 23, and blood-related therapies like ESPO (human erythropoietin), NESP (an erythropoiesis stimulating agent), and GRAN (a human colony-stimulating factor). Further products in its lineup address diverse medical needs: G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for opioid-induced constipation; Nouriast/Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. Other significant offerings are PecFent, a nasally administered spray; POTELIGEO, a humanized monoclonal antibody targeting CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a recombinant protein promoting platelet production; and SANCUSO for managing nausea and vomiting. Beyond its current offerings, Kyowa Kirin is actively involved in pipeline development, notably through a strategic collaboration with Amgen Inc. for the joint development and commercialization of KHK4083. This Phase 3-ready, fully human anti-OX40 monoclonal antibody is being developed to treat atopic dermatitis. Established in Tokyo, Japan, in 1949, the company changed its name from Kyowa Hakko Kirin Co., Ltd. to Kyowa Kirin Co., Ltd. in June 2019. It operates as a subsidiary of Kirin Holdings Company, Limited.
Prix de l'action
$15.74
Capitalisation boursière
$8.24B
Changement (1 jour)
1.62%
Changement (1 an)
4.76%
Pays
JP
Échange Kyowa Kirin Co., Ltd. (4151)
Catégorie
Healthcare
Revenus pour Kyowa Kirin Co., Ltd. (4151)
Revenus en Jun 2026 TTM : $3.46B
Selon les derniers rapports financiers de Kyowa Kirin Co., Ltd., le chiffre d'affaires actuel de l'entreprise (TTM) est de $3.46B. En 2024, l'entreprise a réalisé un chiffre d'affaires de $3.16B une augmentation par rapport à le chiffre d'affaires de l'année 2023, qui était de $3.14B. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Kyowa Kirin Co., Ltd. de 2001 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $3.46B | 9.14% |
| 2025 | $3.17B | 0.34% |
| 2024 | $3.16B | 0.66% |
| 2023 | $3.14B | 3.21% |
| 2022 | $3.04B | -0.71% |
| 2021 | $3.06B | -0.76% |
| 2020 | $3.08B | 9.59% |
| 2019 | $2.81B | -10.98% |
| 2018 | $3.16B | 0.78% |
| 2017 | $3.14B | 6.93% |
| 2016 | $2.93B | -3.09% |
| 2015 | $3.03B | 8.70% |
| 2014 | $2.78B | -13.92% |
| 2013 | $3.23B | -16.03% |
| 2012 | $3.85B | -13.50% |
| 2011 | $4.45B | -12.59% |
| 2010 | $5.10B | 53.02% |
| 2009 | $3.33B | -15.32% |
| 2008 | $3.93B | 30.94% |
| 2007 | $3.00B | -0.05% |
| 2006 | $3.00B | -10.40% |
| 2005 | $3.35B | 0.11% |
| 2004 | $3.35B | 10.24% |
| 2003 | $3.04B | 6.34% |
| 2002 | $2.86B | -4.58% |
| 2001 | $2.99B | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $79.67B | 2,204.73% |
US
|
|
| $99.34B | 2,773.76% |
US
|
|
| $64.39B | 1,762.69% |
US
|
|
| $66.40B | 1,820.95% |
US
|
|
| $77.52B | 2,142.61% |
CH
|
